(Reuters)—Initial data from clinical trials testing whether patients with severe coronavirus illness can be helped by a rheumatoid arthritis drug sold by Regeneron Pharmaceuticals Inc and Sanofi SA may come as early as next week, Regeneron’s chief scientific officer told Reuters. “We could be one to two weeks—at most a month or so—away from knowing…
Articles by Natasha Yetman
Amneal Running Out of HCQ Raw Material Due to Finnish Restrictions
NEW YORK/HELSINKI (Reuters)—Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the anti-malarial drug hydroxychloroquine (HCQ) that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker’s chief executives. Amneal has committed to producing about 20 million…
Cortisone Shots Less Effective Than PT for Arthritis-Related Knee Pain
(Reuters Health)—People with stiff and aching knees due to arthritis get better relief from physical therapy than from cortisone injections, according to a one-year military study comparing the two treatments. A multi-disciplinary team of doctors reports in The New England Journal of Medicine that people who initially scored 107 on a 241-point scale measuring a…
FDA Accelerates Approvals of Generic Versions of HCQ
On April 7, the FDA approved an Abbreviated New Drug Application (ANDA) for Hydroxychloroquine Sulfate Tablets USP, 200 mg, for the treatment of: 1) uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; 2) chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and 3) treatment of acute and chronic…
Should Biologic Therapy in Dermatology Be Interrupted During the Pandemic?
NEW YORK (Reuters Health)—The ongoing novel coronavirus pandemic has raised concerns about whether biologic therapy could make psoriasis patients more susceptible to SARS-CoV-2, the virus behind COVID-19. Mark Lebwohl, MD, from Icahn School of Medicine at Mount Sinai Hospital in New York and colleagues address this issue in a letter in the Journal of the…
Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug
PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an…
U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand
April 1 (Reuters)—The U.S. Food and Drug Administration (FDA) said malaria drugs hydroxychloroquine and related chloroquine are in shortage due to a surge in demand because of the coronavirus pandemic. The drugs, which have been tried with some success to treat the illness caused by the virus, were added to the agency’s website that lists…
No Evidence to Support Biologic Switching Guidelines for JIA
NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…
Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada…
COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials
(Reuters)—U.S. drugmakers Eli Lilly and Co. and Bristol Myers Squibb said they are delaying the start of new clinical trials in part to free up doctors and healthcare facilities to deal with the surge in patients infected with the new coronavirus. Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 97
- Next Page »